TransMedics Group, Inc. (TMDX): Price and Financial Metrics

TransMedics Group, Inc. (TMDX): $31.45

-0.05 (-0.16%)

POWR Rating

Component Grades














  • TMDX scores best on the Growth dimension, with a Growth rank ahead of 30.17% of US stocks.
  • TMDX's strongest trending metric is Momentum; it's been moving down over the last 179 days.
  • TMDX's current lowest rank is in the Value metric (where it is better than 15.64% of US stocks).

TMDX Stock Summary

  • TMDX's went public 2.91 years ago, making it older than merely 8.91% of listed US stocks we're tracking.
  • TMDX's price/sales ratio is 23.77; that's higher than the P/S ratio of 93.75% of US stocks.
  • In terms of volatility of its share price, TMDX is more volatile than 80.53% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to TransMedics Group Inc, a group of peers worth examining would be GKOS, RADA, IPWR, EGAN, and CLIR.
  • TMDX's SEC filings can be seen here. And to visit TransMedics Group Inc's official web site, go to

TMDX Valuation Summary

  • TMDX's EV/EBIT ratio is -35; this is 219.45% lower than that of the median Healthcare stock.
  • Over the past 28 months, TMDX's price/earnings ratio has gone down 12.1.
  • Over the past 28 months, TMDX's price/sales ratio has gone down 2.9.

Below are key valuation metrics over time for TMDX.

Stock Date P/S P/B P/E EV/EBIT
TMDX 2021-08-31 30.2 10.2 -30.2 -35.0
TMDX 2021-08-30 28.6 9.6 -28.6 -33.2
TMDX 2021-08-27 29.5 9.9 -29.4 -34.2
TMDX 2021-08-26 28.5 9.6 -28.4 -33.0
TMDX 2021-08-25 26.5 8.9 -26.4 -30.7
TMDX 2021-08-24 26.1 8.8 -26.0 -30.3

TMDX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TMDX has a Quality Grade of D, ranking ahead of 12.13% of graded US stocks.
  • TMDX's asset turnover comes in at 0.2 -- ranking 143rd of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows TMDX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.200 0.677 -0.179
2021-03-31 0.162 0.659 -0.164
2020-12-31 0.179 0.649 -0.186
2020-09-30 0.183 0.646 -0.227
2020-06-30 0.202 0.609 -0.280
2020-03-31 0.243 0.610 -0.314

TMDX Price Target

For more insight on analysts targets of TMDX, see our TMDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $53.00 Average Broker Recommendation 1.5 (Moderate Buy)

TMDX Stock Price Chart Interactive Chart >

Price chart for TMDX

TMDX Price/Volume Stats

Current price $31.45 52-week high $35.37
Prev. close $31.50 52-week low $10.00
Day low $30.00 Volume 384,943
Day high $31.74 Avg. volume 243,407
50-day MA $26.94 Dividend yield N/A
200-day MA $23.72 Market Cap 879.91M

TransMedics Group, Inc. (TMDX) Company Bio

TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.

TMDX Latest News Stream

Event/Time News Detail
Loading, please wait...

TMDX Latest Social Stream

Loading social stream, please wait...

View Full TMDX Social Stream

Latest TMDX News From Around the Web

Below are the latest news stories about TransMedics Group Inc that investors may wish to consider to help them evaluate TMDX as an investment opportunity.

Transmedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q4 2021 Results - Earnings Call Transcript

Transmedics Group, Inc. (TMDX) Q4 2021 Earnings Conference Call February 23, 2022, 17:00 ET Company Participants Brian Johnston - Gilmartin Group Waleed Hassanein - Founder, MD, CEO, President & Director Stephen Gordon - CFO. Treasurer & Secretary Conference Call Participants William Plovanic - Canaccord Genuity Michael Ott - Oppenheimer Bryan...

SA Transcripts on Seeking Alpha | February 24, 2022

TransMedics (TMDX) Reports Q4 Loss, Tops Revenue Estimates

TransMedics (TMDX) delivered earnings and revenue surprises of -6.98% and 26.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

TransMedics Reports Fourth Quarter and Full Year 2021 Financial Results

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2021.

Yahoo | February 23, 2022

TransMedics to Present at the Cowen 42nd Annual Healthcare Conference

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team will present virtually at the upcoming Cowen 42nd Annual Healthcare Conference. Management is scheduled to present on Wednesday, March 9, 2022, at 9:50 a.m. Eastern Standard Time.

Yahoo | February 22, 2022

Analysts Expect Breakeven For TransMedics Group, Inc. (NASDAQ:TMDX) Before Long

We feel now is a pretty good time to analyse TransMedics Group, Inc.'s ( NASDAQ:TMDX ) business as it appears the...

Yahoo | February 21, 2022

Read More 'TMDX' Stories Here

TMDX Price Returns

1-mo 7.82%
3-mo 14.36%
6-mo 64.14%
1-year -5.21%
3-year 8.71%
5-year N/A
YTD 64.14%
2021 -3.72%
2020 4.68%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5229 seconds.